|U.S. stocks rose on Wednesday, with the Dow Advancing|
|By Josh Gee|
|Wednesday, 05 November 2014 20:36|
After the Republican Party took control of the Senate in the midterm elections, as expected, and following a stronger-than-anticipated report on the labor market, some weak earnings in the tech sector capped gains in the Nasdaq, but the beaten-down energy sector rallied on hopes a Republican majority could lead to new legislation that impacts the group.That includes approval of oil and gas pipelines and reforms of crude and natural gas export laws. Today was the PDUFA date for the FDA's review of AEterna Zentaris Inc. (USA) (NASDAQ:AEZS) NDA for macimorelin acetate for the inducement of growth hormone release to evaluate Adult Growth Hormone Deficiency. The company submitted the filing on November 5, 2013.Investors apparently expect good news. Shares are up nicely today on a 4x surge in volume.
WellCare Health Plans, Inc. (NYSE:WCG) Q3 results: Total Revenues: $3,407.5M (+36.3%), Premium: $3,337.9M (+34.7%); Total Expenses: $3,338M (+39.5%); Operating Income: $69.5M (-34.9%); Net Income: $19.3M (-69.8%); EPS: $0.44 (-69.7%); Quick Assets: $1550.5M (+4.6%); CF Ops: $179.4M (-21.9%).
The FDA designates Merrimack Pharmaceuticals Inc. (NASDAQ:MACK) investigational product candidate, MM-141, an Orphan Drug for the treatment of pancreatic cancer.MM-141 is a tetravalent bispecific antibody designed to block tumor survival signals by targeting receptor complexes containing IGF-1R and ErbB3 (HER3), both of which activate a major cellular signalling pathway that allows tumors to grow and develop resistance to therapies.
Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) Q3 results: Revenues: $14.7M (-12.0%); COGS: $0.6M (+50.0%); R&D Expense: $27.6M (-38.8%); SG&A: $33.6M (-10.2%); Net Loss: ($50.1M) (+24.4%); Loss Per Share: ($0.27) (+25.0%); Quick Assets: $273.5M (+15.3%); CF Ops:($131.9M) (+22.5%).
Nu Skin Enterprises (NYSE:NUS) is down 22% premarket on robust volume in response to softer Q4 guidance. CFO Ritch Wood says the strength of the U.S. dollar will reduce Q4 results by ~$50M compared to Q4 2013 and ~$30M sequentially. The company estimates LTO sales of $20M compared to $350M a year ago. It expects total revenues of $590M - 610M and EPS of $0.72 - 0.77.